Novavax Stock News

The first batch of Nuvaxovid is expected to arrive in Singapore in the next few months. . Read more at straitstimes.com.

February 14, 2022 11:23 AM SINGAPORE - The Covid-19 vaccine developed by Novavax has been approved for individuals aged 18 and above, said the Health Sciences Authority (HSA) on Monday (Feb 14).

SINGAPORE: The Health Sciences Authority (HSA) has granted interim authorisation for Novavaxs Nuvaxovid COVID-19 vaccine to be used in Singapore, it announced on Monday (Feb 14). The vaccine will be allowed for use in individuals aged 18 and above on Feb 3. The vaccination regimen comprises two doses of

Singapore''s Health Sciences Authority (HSA) said on Monday it has granted an interim authorisation for Novavax''s COVID-19 vaccine.

Aussies can now make a booking to get the Novavax Covid vaccine. The health minister hopes it will give the unvaccinated an extra push to get the jab. Here''s how it''s different to the rest

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate proceedings, and the week also witnessed presentations at conferences and a couple of initial public offerings. Pfizer, Inc.''s (NYSE: PFE ) fourth-quarter topline growth trailed expectations, exerting downward pressure on the stock. Modular Medical, Inc. (NASDAQ: MODD ) and TC BioPharm (Holdings) plc American Depositary Shares (NASDAQ: TCBP ) debuted on Wall Street following their IPOs. Novavax, Inc. (NASDAQ: NVAX ) came under pressure midweek after a report suggested that the company is lagging very much behind its COVID-19 delivery commitments. Here are the key catalysts that can move stocks in the biotech space in the coming week: Conferences SVB Leerink Global Healthcare Conference (virtual event): Feb. 14-18 17th Congress Of European Crohn''s and Colitis Organization, or ECCO (virtual event): Feb. 16-19 ASCO Genitourinary Cancers Symposium (hybrid event): Feb. 17-19, in Moscone Center, San Francisco, California and online PDUFA Dates The Food and Drug Administration is scheduled to rule on Agios Pharmaceuticals, Inc.''s (NASDAQ: AGIO ) new drug application for mitapivat, its most advanced drug candidate, as a treatment option for pyruvate kinase deficiency.

Benedikt Richter, a 40-year-old teacher in the southwest German city of Kaiserslautern, long held out against getting vaccinated against COVID-19. He felt uneasy about the novelty of the mRNA | February 13, 2022

Germans pin hopes on Novavax moving the needle among anti-vaxxers

Peloton leads a list of stocks that have fallen from pandemic-era highs.

The company's coronavirus vaccine tests very well on adolescents.

The company''s coronavirus vaccine tests very well on adolescents.

Australian health authorities are hoping the availability of the Novavax COVID-19 vaccine from Monday will inject new momentum into the program.9 per cent of Australians over 16 are double-dosed, according to official figures.

NOVAVAX said Thursday its Covid vaccine was 82 percent effective among adolescents during the period when the Delta variant was dominant, and the US biotech now plans to submit for regulatory approval in this age group. The two-dose vaccine, which is based on synthetic proteins that mimic the spikes that dot the surface of the virus, was found to be safe and effective among more than 2,200 adolescents ages 12 through 17 as part of a phase three clinical trial carried out in the US, the company said in a statement. "We are encouraged by the results in this adolescent population given the ongoing need for alternative vaccine options," said Filip Dubovsky, the company''s chief medical officer. "We believe the Novavax vaccine could be a differentiated option for this younger population given its established protein-based technology already used in other vaccines, and the positive responses demonstrated against variants." The Pfizer vaccine is currently the only authorized shot for teens but comes with certain risks, particularly for adolescent males, of heart inflammation.